Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFRADURE Biopump + Ribavirin for Genotype 3 HCV
NCT01433133Phase 2Terminated
- Sponsor
- Aevi Genomic Medicine
- Start
- Oct 2012
- Primary completion
- Oct 2013
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
01
Overview
Phase 2, open-label, single-arm trial of Infradure in hepatitis C virus infection, sponsored by Aevi Genomic Medicine. Primary endpoint: Sustained Virologic Response at 24 weeks. Started Oct 2012; status: terminated.
02
Drugs
Infradure
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT01433133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01433133.